Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today that James “Jim” Borneman has been named Chief Operating Officer, effective immediately. Jim will be responsible for day-to-day operational oversight as Bryn prepares for the U.S. Food and Drug Administration approval and market launch of its innovative intranasal spray UTULY™, an investigational self-administered form of epinephrine being studied for the treatment of type 1 allergic reactions, including anaphylaxis.
“Jim brings essential commercialization experience to Bryn as we enter the next critical phase of bringing our needle-free epinephrine alternative, UTULY, to market,” said Sandy Loreaux, CEO. “Anaphylaxis can be a life-threatening event. We have made great strides in meeting the demands of the allergy community by developing an ideal delivery system that provides fast and sustained levels of epinephrine. We look forward to Jim’s leadership at the helm of our operations as we seamlessly bring our innovative technology to market.”
Jim is an accomplished leader with extensive experience across many technical, operational, and commercial roles. In addition to participating in multiple new product launches within a range of therapeutic areas during his career, Jim also most recently led the successful integration of a multi-billion-dollar acquisition as Head of the Kadmon Integration office at Sanofi.
Jim served at Sanofi for more than 20 years, where he continuously advanced to levels of increasing responsibility in a variety of functional areas, including finance, forecasting, sales operations, business analytics, sales and market access. In his early career, Jim was a Senior Financial Analyst, Treasury Operations with Bethlehem Steel. Before joining Bethlehem Steel, he served as a Captain in the Aviation branch of the United States Army. Jim has a Master of Business Administration, with a concentration in Finance, from Lehigh University. He earned a Bachelor of Science in Engineering Management, with a concentration in Civil Engineering, at the United States Military Academy at West Point. Jim is also a Chartered Financial Analyst.
About Bryn Pharma
Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit www.brynpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230327005498/en/
Rebecca Novak Tibbitt